ABSTRACT: Many aromatic amines and heterocyclic aromatic amines (HAAs) are known carcinogens for animals, and there is also strong evidence of some in human cancer. The activation of these compounds, including some arylamine drugs, involves N-hydroxylation, usually by cytochrome P450 enzymes (P450) in Family 1 (1A2, 1A1, and 1B1). We previously demonstrated that the bioactivation product of the anticancer agent 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203), an N-hydroxylamine, can be reduced by P450 2S1 to its amine precursor under anaerobic conditions and, to a lesser extent, under aerobic conditions [Wang, K., and Guengerich, F. P. (2012) Chem. Res. Toxicol. 25, 1740−1751]. In the study presented here, we tested the hypothesis that P450 2S1 is involved in the reductive biotransformation of known carcinogenic aromatic amines and HAAs. The N-hydroxylamines of 4-aminobiphenyl (4-ABP), 2-naphthylamine (2-NA), and 2-aminofluorene (2-AF) were synthesized and found to be reduced by P450 2S1 under both anaerobic and aerobic conditions. The formation of amines due to P450 2S1 reduction also occurred under aerobic conditions but was less apparent because the competitive disproportionation reactions (of the N-hydroxylamines) also yielded amines. Further, some nitroso and nitro derivatives of the arylamines could also be reduced by P450 2S1. None of the amines tested were oxidized by P450 2S1. These results suggest that P450 2S1 may be involved in the reductive detoxication of several of the activated products of carcinogenic aromatic amines and HAAs.
■ INTRODUCTION
P450 enzymes catalyze a variety of reactions and are of significant importance in the areas of drug metabolism and toxicology.
1,2 On the basis of analyses of marketed drugs, ∼75% of drug metabolism reactions involve P450s; five P450s (1A2, 2C9, 2C19, 2D6, and 3A4) account for ∼90% of the P450 reactions. 3, 4 Another recent analysis indicated that 66% of carcinogens are bioactivated by P450s, and three Family 1 P450s show dominant roles, involved in ∼50% of the total activations attributed to P450s (1A1, 20%; 1A2, 17%; 1B1, 11%). 5 Aromatic amines [arylamines (Scheme 1); e.g., 4-aminobiphenyl (4-ABP), 2-naphthylamine (2-NA), 2-aminofluorene (2-AF)] are important industrial intermediates for the production of azo dyes and complex chemicals and are also used as antioxidants in rubber manufacturing processes. 6, 7 Rehn first reported the association of exposure to aromatic amines in 1895 with the incidence of bladder cancer among German and Swiss workers in aniline dye factories. 8 Further studies have shown that aromatic amines induce tumors at multiple sites in rodents, dogs, and other experimental laboratory animals as well. 6,7,9−11 Heterocyclic aromatic amines [HAAs (Scheme 1); e.g., 2-amino-3-methylimidazo [4,5- f ]quinoline (IQ), 2-amino-3,8-dimethylimidazo [4,5-f ] quinoxaline (MeIQx), and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP)] are produced in grilled and charred meats. 12, 13 Several HAAs have also been detected in beer, wine, 14 and cigarette smoke condensate. 15, 16 The Maillard reaction is believed to be involved in the formation of the imidazo-containing HAAs when amino acids and carbohydrates are heated together, 17, 18 and other HAAs may form through the pyrolysis of amino acids and proteins. 19 Extensive studies have shown that HAAs are highly genotoxic in bacterial and mammalian cells and exhibit strong carcinogenic effects in experimental animals.
aryl hydrocarbon receptor (AhR). 37 P450 1A2 is expressed almost exclusively in liver in humans (10−15% of total P450), 38 but P450 1A1 and 1B1 are generally not present in liver but expressed in extrahepatic tissues at various levels. 39 A number of in vitro and in vivo studies have shown that P450 1A2 plays a major role in the bioactivation of aromatic amines and HAAs in rodents and humans. 30, 40, 41 The human genome has 57 P450 genes. P450 2S1 is one of ∼13 that are classified as "orphans" with only limited evidence of function. 42 P450 2S1 mRNA has been detected in liver, skin, tumors, and other tissues, 43−46 and the gene is regulated by the AhR. 47, 48 The sites of expression and mode of regulation suggest that P450 2S1 might be involved in the process of chemical carcinogenesis. 45 Recently, attenuation of P450 2S1 by siRNA has been shown to enhance cell proliferation and migration in bronchial epithelial cells. 49 However, a number of carcinogens have been tested and shown not to be activated by P450 2S1. 50 Retinoic acid was reported as a substrate for P450 2S1, 44 but subsequent efforts by others have failed to reproduce these results. 51, 52 The first repeatedly demonstrated reaction for P450 2S1 is the anaerobic reduction of a di-N-oxide anticancer prodrug, 1,4-bis{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione (AQ4N), to its amino derivative, 1,4-bis{[2-(dimethylamino)ethyl]amino}-5,8-dehydroxyanthracene-9,10-dione (AQ4). 51, 52 Previously, we demonstrated that an N-hydroxylarylamine, 2-(4-hydroxylamino-3-methylphenyl)-5-fluorobenzothiazole (HONH-5F 203), can be reduced to its amine precursor, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, an anticancer agent), by P450 2S1 under anaerobic conditions. 53 In this study, several N-hydroxylarylamines and nitroso and nitro derivatives of common carcinogenic aromatic amines and HAAs were synthesized and shown to be reduced by P450 2S1. The rates of P450 2S1-catalyzed anaerobic reductions of the Nhydroxylarylamines were determined. However, N-hydroxyphenacetin (the activated product of the analgesic drug phenacetin 54 ) was not reduced by P450 2S1. Our results suggest that P450 2S1 may be involved in the detoxication of the activated products of a number of aromatic amines and HAAs.
■ EXPERIMENTAL PROCEDURES
Caution: Many of the compounds used in this study are carcinogens and should be handled with care! Gloves, lab coats, and safety goggles should be worn when handling these compounds. All commercially obtained solvents and other chemicals were used directly without further purification. 4-Nitrophenetole, 1-aminonaphthalene, 2-aminonaphthalene, and 2-nitrofluorene were purchased from Sigma-Aldrich (St. Louis, MO). 2-Nitronaphthalene, 4-nitrobiphenyl, NO 2 -IQ, NO 2 -MeIQx, and NO 2 -PhIP were kindly provided by Robert. J. Turesky (Wadsworth Center, Albany, NY). NMR data were obtained with a 400 MHz Bruker NMR spectrometer, using the solvents noted, at Vanderbilt. UV spectra were obtained (online) with a Waters Acquity UPLC system equipped with a photodiode array detector (Waters, Milford, MA).
Chemical Synthesis. N-Hydroxyphenacetin. The title compound was prepared using a modification of a previously reported procedure. 54 4-Nitrophenetole (0.10 g, 0.60 mmol) was reduced to N-hydroxyphenetidine in 2 mL of a C 2 H 5 OH/H 2 O mixture (3:1, v/v) by Zn dust (0.16 g, 2.4 mmol) in the presence of 0.032 g of NH 4 Cl. The reaction mixture was diluted with 4 mL of cold H 2 O and extracted with (C 2 H 5 ) 2 O (3 × 5 mL). The combined (C 2 H 5 ) 2 O extracts were evaporated to dryness in vacuo at 23°C. The residue was dissolved in 2 mL of (C 2 H 5 ) 2 O in the presence of a slurry of NaHCO 3 (0.08 g in 0.25 mL of water) at 0°C, and 2.5% acetyl chloride (47 mg, 0.60 mmol) in (C 2 H 5 ) 2 O (w/v) was added slowly to the mixture. The resulting mixture was stirred for 2 h and extracted with (C 2 H 5 ) 2 O (3 × 5 mL). The combined (C 2 H 5 ) 2 O layers were washed sequentially with H 2 O and brine and dried over anhydrous Na 2 SO 4 . The solvent was removed in vacuo, and flash column chromatography on silica gel using (C 2 H 5 ) 2 N-Hydroxylamines and Nitroso Compounds. HONH-5F 203, 53 4-HONH-biphenyl, 2-HONH-naphthalene, 2-HONH-fluorene, and HONH-PhIP were prepared by the reduction of the corresponding nitro derivatives with hydrazine and Pd/C at 0°C for 30 min to 2 h. 56, 57 HONH-IQ and HONH-MeIQx were prepared by the reduction of nitro analogues with ascorbic acid in (CH 3 ) 2 SO as described by Turesky et al. 57 NO-5F 203 and 4-NO-biphenyl were prepared by the oxidation of HONH-5F 203 and 4-HONH-biphenyl with K 3 Fe(CN) 6 under ambient conditions for 3 h as reported previously. 53 Enzyme Preparations. Recombinant human P450 2S1 was expressed and purified in Escherichia coli membranes as previously described. 50 NADPH-P450 reductase (NPR) was expressed in E. coli and purified as described previously. 58 Incubation Conditions. A typical incubation 59 mixture contained purified P450 2S1 (0.5 μM), NPR (1 μM), 160 μM L-α-dilauroyl-snglycero-3-phosphocholine, an NADPH-generating system (10 mM glucose 6-phosphate, 0.5 mM NADP + , and 4 μg/mL yeast glucose-6-phosphate dehydrogenase), and the appropriate substrate (100 μM) in 0.10 M sodium N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES) buffer (pH 7.4, containing 1 mM EDTA). The incubations were performed at 37°C for 30 min. Cold CH 2 Cl 2 (2-fold volume) was added to terminate each reaction, and the resulting mixtures were separated by centrifugation at 2000g for 3 min. The lower organic layer was transferred and dried under a N 2 stream. The residue was dissolved in CH 3 CN for HPLC and LC−MS analysis.
Anaerobic Incubations. Qualitative anaerobic experiments were performed in Thunberg tubes, as previously described. 53 A typical 500 μL incubation mixture contained 0.5 μM P450, 1.0 μM NPR, 160 μM L-α-1,2-dilauoryl-sn-glycero-3-phosphocholine, 100 mM sodium HEPES buffer (pH 7.4), 1 mM EDTA, and 100 μM substrate [from a freshly prepared 10 mM (CH 3 ) 2 SO stock]. When the desired level of anaerobicity was achieved (after five cycles of vacuum and Ar), an NADPH-generating system was added to the incubation mixture from the neck of the tube. The reaction mixtures were incubated at 37°C for 10−30 min, the reactions terminated by the addition of 1.0 mL of cold CH 3 CN, and the mixtures analyzed by HPLC.
For comparisons, anaerobic incubations were conducted with P450 1A1, 1A2, 2S1, 2W1, and 3A4 at the same concentration (0.2 μM) for 10 min.
Steady-State Kinetic Measurements of Anaerobic Reduction of HONH-5F 203. Anaerobic incubations were conducted under a N 2 atmosphere in a glovebox (Labconco, Kansas City, MO). The concentrations of P450 and the NADPH-generating system and buffer conditions remained the same as those employed in the qualitative studies. A stock solution was made of freshly prepared HONH-5F 203 in (CH 3 ) 2 SO, and the concentration was determined colorimetrically. 60 A series of standard solutions at different concentrations was prepared from the stock solution by dilution. Reactions with different substrate concentrations (ranging from 0 to 200 μM) were conducted, in duplicate, at 37°C for 10 min. After the reactions had been quenched with CH 2 Cl 2 (2-fold volume), 2-phenylbenzothiazole (5 μL, 0.1 mM) was added to each reaction mixture as an internal standard. The mixtures were centrifuged at 2000g for 3 min, and the organic layers were transferred and dried under a stream of N 2 . The residues were dissolved in CH 3 CN for HPLC analysis.
Determination of Rates of Anaerobic Reduction of 4-NHOHBiphenyl, 2-NHOH-Naphthalene, and 2-NHOH-Fluorene to the Corresponding Amines by P450 2S1. Anaerobic incubations were conducted under a N 2 atmosphere in a glovebox, as in the steady-state kinetic studies for HONH-5F 203 reduction. The rates of reduction were measured at a single substrate concentration (10 μM). Standard solutions (1 mM, determined by colorimetric assay) of 4-NHOHbiphenyl, 2-NHOH-naphthalene, and 2-NHOH-fluorene in CH 3 CN were prepared from freshly prepared samples. Under the conditions used in this study, optimal P450 2S1 concentrations for 4-NHOHbiphenyl, 2-NHOH-naphthalene, and 2-NHOH-fluorene were 500, 25, and 50 nM, respectively (the corresponding concentrations of NPR were 1, 0.5, and 0.5 μM, respectively). The concentrations of the NADPH-generating system and buffer conditions were the same as in a typical incubation, vide supra. A standard solution (5 μL) was added to each enzyme reaction mixture (volume of 500 μL) and each mixture incubated at 37°C. Reactions were terminated by addition of CH 2 Cl 2 (1.0 mL) after 0, 1, 2, 3, 4, and 5 min. For each compound, incubations were performed in duplicate at every time point. Incubations devoid of P450 2S1 were performed as controls. 1-Naphthylamine (5 μL, 500 μM) was added to each sample as an internal standard, and the mixtures were centrifuged. The isolated organic layers were transferred and dried under a stream of N 2 , and the residues were dissolved in CH 3 CN for HPLC analysis.
HPLC and LC−MS Analysis of the Reduction Reactions. The reduced reaction products of hydroxylamine, nitroso, and nitro compounds were analyzed using a Waters Acquity UPLC system equipped with a photodiode array detector (Waters) and an octadecylsilane (C 18 ) reversed-phase column (5 μm, 2.1 mm × 250 mm, Hypersil GOLD, Thermo Scientific, Odessa, TX). Absorbance was integrated (210−400 nm). The column temperature was maintained at 25°C. LC conditions for phenacetin, 4-ABP, 2-NA, 2-AF, and 5F 203 derivatives were as described previously. 53 LC−MS and LC−MS/MS analyses were performed on a Waters Acquity UPLC system coupled to a Thermo-Finnigan LTQ ion trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA). The same LC conditions were used for each sample as in the HPLC analysis. Samples were generally analyzed in the atmospheric-pressure chemical ionization (APCI) positive ion mode. MS conditions were optimized for each amine derivative as follows: capillary temperature, 275°C; vaporizer temperature, 450°C; source voltage, 6.0 kV; sheath gas flow, 50.0; auxiliary gas flow, 5.0; sweep gas flow, 5.0; and in-source fragmentation, 10 V.
Colorimetric Assay for N-Hydroxyarylamines. 60 From a typical solution containing 5−10 mM N-hydroxyarylamine, a 1−2 μL aliquot was added to a tube containing 0.96 mL of the color reagent. 60 The sample was mixed vigorously using a vortex device. After 3 min, 40 μL of stabilizer (H 3 PO 4 , 20 mM) was added to the mixture. The sample was mixed thoroughly, and A 535 was measured, with reference to a sample containing all of the reagents except Nhydroxyarylamine as a control (ε 535 = 39200 M −1 cm −1 ). P450 2S1 Binding Assay (with HONH-5F 203). Binding spectra of P450 with HONH-5F 203 were recorded with purified P450 2S1 (23°C) using a UV−visible scanning spectrophotometer (Aminco DW-2a, OLIS, Bogart, GA). A baseline was recorded (350−700 nm) using two 1.0 mL glass cuvettes (1 cm path length) containing equal volumes of 100 mM potassium phosphate buffer (pH 7.4) containing 20% glycerol (v/v). Purified P450 2S1 was added to the sample cuvette (final concentration of 5 μM). The same volume of the buffer was added to the reference cuvette. Equal amounts of freshly prepared aliquots of HONH-5F 203 [dissolved in (CH 3 ) 2 SO] were added to both cuvettes. Difference spectra were collected (350−700 nm) after an equilibration period of 1 min [total volume of (CH 3 ) 2 SO of ≤2%].
systems containing NPR and NADPH, as judged by HPLC− UV assays. No products were detected from an incubation mixture of [ 14 C]lauric acid with P450 2S1 using HPLC (coupled online with scintillation counting).
Anaerobic Incubation of N-Hydroxyphenacetin with P450 2S1. N-Hydroxyphenacetin was incubated with P450 2S1 at 37°C for 20 min under anaerobic or aerobic conditions, with an HPLC peak at a t R of 4.7 min corresponding to Nhydroxyphenacetin. N-Hydroxyphenacetin was stable under all conditions tested in this study ( Figure S1 of the Supporting Information). Neither P450 2S1, NPR, NADPH, nor the combination changed the N-hydroxyphenacetin to any products.
Anaerobic Reduction of 4-HONH-Biphenyl, 2-HONHNaphthalene, and 2-HONH-Fluorene with P450 2S1. NArylhydroxylamines are unstable substances and readily undergo disproportionation reactions (Scheme 2) to yield arylamines and nitroso derivatives in neutral or basic media. 61, 62 The nitroso products can further condense with N-arylhydroxylamines to produce azoxy compounds. 63 In anaerobic incubations of all three N-arylhydroxylamines with P450 2S1 (in the presence of NPR and an NADPH-generating system), significantly larger amounts of the corresponding arylamines were formed [than under other conditions when P450 2S1 or an NADPH-generating system was absent ( Similarly, HPLC analyses of the anaerobic incubation mixtures of P450 and 2-HONH-fluorene (which disappeared completely after incubations) also showed four major peaks ( Figure S5 Anaerobic Reduction of HONH-5F 203, 4-HONHBiphenyl, and 2-HONH-Fluorene with Other Human P450s. HONH-5F 203 can be reduced by P450 2S1 to 5F 203 under anaerobic conditions and (to a lesser extent) under aerobic conditions, as shown previously. 53 Interestingly, when it was incubated with P450 1A1 or 2W1 at 37°C for 30 min under anaerobic conditions ( Figure S12 of the Supporting Information), HONH-5F 203 (t R = 6.1 min) was also be reduced to 5F 203 (t R = 6.4 min). To evaluate the relative catalytic efficiency of P450 2S1 for the reduction of aromatic Nhydroxylamines, anaerobic incubations of 4-HONH-biphenyl ( Figure S13 of the Supporting Information) and 2-HONHfluorene ( Figure S14 of the Supporting Information) with P450 1A1, 1A2, 2S1, 2W1, and 3A4 were conducted in parallel. 4-HONH-biphenyl (t R = 5.5 min) disappeared almost completely, and significantly larger amounts of azoxybiphenyl (t R = 8.1 min) were formed in the presence of P450s [except for P450 2S1 ( Figure S13A known to be nonenzymatically reduced by NAD(P)H to Nhydroxyarylamines, 64 which could be further reduced by P450 2S1 to arylamines (Scheme 3). Freshly prepared NO-5F 203 53 (containing trace amounts of 5F 203 and HONH-5F 203) was incubated with P450 2S1 at 37°C for 30 min under anaerobic conditions ( Figure 3 ) and aerobic conditions (data not shown). The t R values of 5F 203 (λ max = 347 nm), HONH-5F 203 (λ max = 338 nm), and NO-5F 203 (λ max = 363 nm) were 6.3, 6.0, and 7.4 min, respectively, consistent with our previously reported data. 53 In the absence of P450 2S1, HONH-5F 203 was formed via reduction of NO-5F 203, as the most abundant peak ( Figure 3B , in the presence of NPR and an NADPH-generating system), whereas in the absence of an NADPH-generating system, HONH-5F 203 was less abundant than 5F 203 ( Figure  3C ), suggesting that NADPH was capable of nonenzymatically reducing NO-5F 203 to HONH-5F 203. When P450 2S1 was added, NO-5F 203 disappeared and the predominant product was 5F 203 (the arylamine), indicating that P450 2S1 can catalyze the reduction of HONH-5F 203 to 5F 203 ( Figure  3D ). These results were in accord with our previous observations. 53 Freshly prepared 4-NO-biphenyl (containing trace 4-ABP and azoxybiphenyl) was incubated with P450 2S1 Figure S7B of the Supporting Information)] was produced, in addition to HONH-IQ, indicating that P450 2S1 can catalyze the reduction of HONH-IQ to IQ (the amine). Similar to the results observed for NO 2 -IQ, in the absence of P450 2S1, 2-NO 2 -naphthalene was also partially reduced to yield 2-NHOH-naphthalene as the major product ( Figure 5C ). However, in the presence of P450 2S1, 2-NA was formed almost exclusively and no 2-NHOH-naphthalene was present at a discernible level ( Figure 5D ), suggesting that P450 2S1 can catalyze the reduction of 2-NHOH-naphthalene as well.
HONH-5F 203 Binding to P450 2S1. Titration of HONH-5F 203 with P450 2S1 resulted in a concentrationdependent decrease in absorbance at 417 nm and an increase at 458 nm (Figure 6 ), indicative of interactions between HONH-5F 203 and the heme iron. ) by P450 2S1 were measured at a single substrate concentration of 10 μM, considering only the amine formation contributed by P450 2S1 catalysis (subtracting the amounts of amines in control incubations in which P450 2S1 was absent).
■ DISCUSSION
In this study, P450 2S1 did not exhibit oxidation activity with several common substrates for P450s or a number of aromatic and heterocyclic amines. Although some catalytic activity was reported in the absence of NPR when oxygen surrogates were added, 65, 66 substrates for P450 2S1-catalyzed oxidation under standard conditions have not been identified.
The reduction of N-hydroxylated compounds in rat and hog liver extracts was noted several decades ago. 67−70 For the enzymatic reduction, a microsomal (three-component enzyme system containing cytochrome b 5 , NADH-cytochrome b 5 reductase, and an unidentified third component) 67, 68 and a mitochondrial 69, 70 system have been proposed. In a study of the reduction of amidoxime prodrugs, stearoyl-CoA desaturase was proposed to be involved in the microsomal reductions. 71 The third component for the reduction of N-hydroxylamines in hog liver microsomes was isolated and characterized as a P450 subfamily 2D enzyme. 72 However, a human homologue has not been found. A novel molybdenum-containing enzyme from the mitochondrial fraction, mitochondrial amidoxime reducing component (mARC), was also suggested. 73 Subsequent incubations with cytochrome b 5 , NADH cytochrome b 5 reductase, and mARC exhibited amidoxime reductase activity in vitro. 74, 75 The reduction of N-hydroxylamines in the absence of the third component was also reported (i.e., only cytochrome b 5 and NADH cytochrome b 5 reductase). 76, 77 One caveat of these latter studies is that the 4-HONH-biphenyl used was not freshly prepared, and even in the presence of ascorbic acid, the disproportionation of 4-HONH-biphenyl (which also yields 4-ABP) was still significant under the experimental conditions.
Although most P450 reactions are oxidations, 5 P450s can also catalyze a wide range of reductions, 1 as summarized by Wisloki et al. 78 and more recently by Testa. 79 Generally in the P450 catalytic cycle, the ferrous P450 species binds O 2 tightly and oxidation occurs rapidly (after the addition of the second electron).
1 However, in tissues where only a low concentration of O 2 is present, e.g., in hypoxic cancer cells, 80 reduction becomes more favorable. Ferrous P450 (E m,7 ∼ −300 mV) 81, 82 should be a reasonably good reducing agent if the substrate is in an appropriately bound form and has the potential to accept electrons. Alternatively, the binding of some substrates may block (or partially block) the incorporation of O 2 , which should allow the reduction to occur even under aerobic conditions. 1 It was shown earlier that AQ4N (a di-N-oxide) can be reduced by both P450 2W1 and 2S1 under anaerobic conditions. 51 Subsequently, we found that 5F 203 can undergo P450 1A1-and 2W1-mediated bioactivation in the presence of O 2 , and HONH-5F 203 (one of the reactive intermediates) can be reduced by P450 2S1 under anaerobic conditions and, to a lesser extent, aerobic conditions. 53 In this report, we show that P450 1A1 and 2W1 can also catalyze the reduction of HONH-5F 203 anaerobically, suggesting that the biotransformation pathways might be influenced by the O 2 tension.
The analgesic phenacetin is N-hydroxylated in rodents and humans. 54, 55 Another metabolic pathway for phenacetin is Odeethylation, catalyzed by P450 1A2 to yield acetaminophen. 83 Although acetaminophen is hepatotoxic at high doses, phenacetin induces a high incidence of tumors in the case of chronic use of large doses to animals 84 and was withdrawn from the market because of its possible carcinogenicity. 85 The biotransformation pathways that lead to the formation of DNA adducts for the N-hydroxyphenacetin are similar to that for Nacetyl-2-AF (AAF) and many aromatic amines. 26, 55 We did not observe any reduction of N-hydroxyphenacetin by P450 2S1, under any conditions used, suggesting that P450 2S1 probably is not involved in the biotransformation of N-hydroxyphenacetin. However, it should be pointed out that N-hydroxyphenacetin is a hydroxamic acid, not a hydroxylamine, and we did not pursue the issue of whether P450 2S1 (or other P450s) reduces other hydroxamic acids.
The results in this study demonstrate that human P450 2S1 is capable of catalyzing the reduction of several N-hydroxy aromatic amines and HAAs, especially under anaerobic conditions. P450 2S1 appeared to be the most efficient enzyme among several P450s examined, at least for the anaerobic reductions of 4-HONH-biphenyl and 2-HONH-fluorene. It is worth noting that 4-HONH-biphenyl, 2-HONH-naphthalene, and 2-HONH-fluorene are very unstable molecules, even in the absence of O 2 , and readily undergo disproportionation reactions to yield amine, nitroso, and azoxy derivatives. Thus, the formation of aromatic amines from N-hydroxylamines does not necessarily mean that reduction is occurring; i.e., the difference between the amounts of amine formed with and without P450 2S1 reflects the enzymatic activity, and therefore, the rates of anaerobic reductions of 4-HONH-biphenyl, 2-HONH-naphthalene, and 2-HONH-fluorene were measured in this way. The presence of NADPH slowed the disproportionation to various extents ( Figure 1B , and Figures S3B and S5B of the Supporting Information) when compared to the incubation controls ( Figures 1A, 3A , and 5A), presumably because of nonenzymatic reduction of nitroso species. On the contrary, P450 2S1 accelerated the process of disproportionation ( Figure 1C , and Figures S3C and S5C of the Supporting Information), and some nonreductive pathways for the reaction of oxidized amines have been described previously. 86 The nitroso derivatives of 5F 203 and 4-ABP were reduced by NADPH with NPR to N-hydroxylamines ( Figure 7B ) under anaerobic conditions. In the presence of P450 2S1, as well as NPR, NO-5F 203 was reduced to 5F 203 (amine) almost completely ( Figure 3D ). P450 2S1-catalyzed anaerobic reduction of 4-HONH-biphenyl occurred but was not as efficient as that with HONH-5F 203 ( Figure 4D) . A larger amount of azoxybiphenyl ( Figure 4D ) compared to the incubation control ( Figure 4A ) is due to the fact that no disproportionation can occur because no 4-HONH-biphenyl is formed in the control reaction. Nitroso derivatives of aromatic amines and HAAs can react with hemoglobin-β Cys-93 in the bloodstream to form arylamine−hemoglobin sulfinamide adducts in experimental animals. 87, 88 4-ABP has been reported to have a high fraction of dose (>5%) bound to hemoglobin as sulfinamide adducts. 89 Reduction of nitroso compounds may decrease the level of formation of hemoglobin adducts. The nitroso derivative of IQ has been shown to be reduced by NPR to form the N-hydroxylamine and a trace amount of IQ. 64 Similarly, the nitro derivatives of IQ and 2-NA are also reduced by NPR to N-hydroxylamines as major products ( Figure 5A,C) under anaerobic conditions. If P450 2S1 is also present, Nhydroxylamines are reduced to yield IQ and 2-NA [amines ( Figure 5B,D) ].
In conclusion, our results indicate that human P450 2S1 is capable of catalyzing the reduction of N-hydroxylamine, nitroso, and nitro derivatives of at least several carcinogenic aromatic amines and HAAs to yield amines. This may represent a detoxication pathway for aromatic amines and HAAs, although at this time we cannot judge the extent of the in vivo contribution. 
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